Amgen (AMGN) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Amgen · Health Care · ref. ETF XLV · 85 calls · price $436.99
What the company does: Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines.
📈 Amgen (AMGN) stock price
$436.99+53.0% over range
Aug 28, 25low $271.18 · high $443.84Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
42% recommend buying · 19 analysts
📊 JPI status : Amgen has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 AMGN price target & analyst consensus — price $437
The price target · all analysts combined (19 targets)
Highest target · 1 firm of 19$460+5.3%
Median target · of 19 targets$400-8.5%
Lowest target · 1 firm of 19$333-23.8%
Current price$436.99
Where these 19 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
737%
$440 ↔ $460
Below
1263%
$333 ↔ $405
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $450 (+3.0 %), call made on August 6, 2026, maturing on August 6, 2027 (22 d ago).
The 14 reliable analysts
$403-7.9 %
The 5 other firms
$400-8.5 %
How to read it: the 14 reliable firms are not filtered by optimism — 6 aim above the price, 8 below, hence their $403 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 19 ratings (last 6 months)
Strong Buy00%
Buy842%
Hold1158%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 AMGN price target all
All 24 calls, one by one, with our verdict on each firm.
→ See all 24 targets, analyst by analyst💡 The best analysts on AMGN most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in AMGN? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Amgen? The JPI assistant answers using our backtest data.
💰 Amgen dividend: yield, history & growth › open the full page
2.71%annual yield
📈 Steady dividend — 14 yrs of consecutive dividend increases
That's ~$9.80 per share per year.
📈 Amgen fundamentals: valuation, margins & growth › open the full page
P/E 27.3Net margin 23.0 %Revenue growth +9.5 %Cheap for the growth
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 25 %
2023
Rev +7%Profit +3%
2024
Rev +19%Profit −39%
2025
Rev +10%Profit +89%
🔎 Detailed analyses
🏛️ Which US Congress members hold Amgen (AMGN)?
15 Congress members have disclosed AMGN buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Marjorie Greene 6× · 37%Josh Gottheimer 5× · 56%Kathy Manning 5× · 43%Richard Allen 3× · 42%C. Franklin 2×Jefferson Shreve 2× · 40%Jared Moskowitz 2× · 25%David Taylor 2×Carol Miller 1× · 25%Earl Blumenauer 1× · 38%
✅ Historical analyst reliability on AMGN
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Deutsche Bank ↗ | 100% | +38.2% | 5 |
| Citigroup ↗ | 100% | +29.3% | 9 |
| UBS ↗ | 100% | +21.9% | 4 |
| CFRA | 100% | +15.7% | 2 |
| Truist Securities ↗ | 100% | +11.8% | 3 |
| Jefferies ↗ | 85% | +17.6% | 13 |
| Goldman Sachs ↗ | 80% | +8.1% | 5 |
| Argus Research ↗ | 78% | +15.6% | 9 |
| Piper Sandler ↗ | 74% | +13.1% | 19 |
| Credit Suisse | 69% | +8.3% | 13 |
See the other 14 firms
| Barclays ↗ | 17% | -17.7% | 6 |
| Cantor Fitzgerald ↗ | 29% | -2.9% | 7 |
| TD Cowen ↗ | 33% | -4.5% | 3 |
| Atlantic Equities | 33% | -3.6% | 3 |
| BMO Capital ↗ | 38% | +3.1% | 8 |
| RBC Capital ↗ | 40% | +3.8% | 10 |
| B of A Securities ↗ | 43% | -5.7% | 7 |
| Baird ↗ | 50% | +1.6% | 2 |
| Raymond James ↗ | 50% | +6.3% | 2 |
| Cowen & Co. | 50% | +12.6% | 2 |
| Morgan Stanley ↗ | 57% | +4.3% | 30 |
| Nomura | 67% | +5.8% | 3 |
| SunTrust Robinson Humphrey | 67% | +5.9% | 3 |
| Oppenheimer ↗ | 67% | +9.1% | 21 |
📊 What $1,000 invested in Amgen would be worth › open the full page
In short — $1,000 invested in Amgen 10 years ago would be worth $2,545 today, i.e. +10%/yr on average. Best year: 2025 (+26%), worst: 2021 (+1%). Price performance, excluding dividends.
If I'd invested $1,000 in Amgen
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,175 | +18% |
| 3 years ago | $1,563 | +56% |
| 5 years ago | $1,610 | +61% |
Return by year (Amgen)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | -7% | $933 (-7%) |
| 2025 | +26% | $1,175 (+18%) |
| 2024 | +13% | $1,322 (+32%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Amgen
Loading news…
📋 All analyst calls on AMGN
Filtered on — · ✕ show all
Piper Sandler ↗
Aug 20, 26
▲ Overweight · 🎯$457
Price at call : $439.33 — upside +4%
Today : $436.99 — upside +5%
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
Argus Research ↗
Aug 19, 26
▲ Buy · 🎯$460
Price at call : $442.36 — upside +4%
Today : $436.99 — upside +5%
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
in progress (365j)
matures : Aug 19, 27
matures : Aug 19, 27
■ Neutral neutral · not a buy · 🎯$352
Price at call : $425.28 — gap to target -17%
Today : $436.99 — gap to target -19%
🎯 on AMGN : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Aug 18, 27
matures : Aug 18, 27
Cantor Fitzgerald ↗
Aug 18, 26
■ Neutral neutral · not a buy · 🎯$400
Price at call : $425.28 — gap to target -6%
Today : $436.99 — gap to target -8%
🎯 on AMGN : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Aug 18, 27
matures : Aug 18, 27
■ Equal-Weight neutral · not a buy · 🎯$380
Price at call : $419.38 — gap to target -9%
Today : $436.99 — gap to target -13%
🎯 on AMGN : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Aug 14, 27
matures : Aug 14, 27
Guggenheim ↗
Aug 10, 26
■ Neutral neutral · not a buy · 🎯$388
Price at call : $414.3 — gap to target -6%
Today : $436.99 — gap to target -11%
🎯 on AMGN : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Aug 10, 27
matures : Aug 10, 27
■ Neutral neutral · not a buy · 🎯$405
Price at call : $417.2 — gap to target -3%
Today : $436.99 — gap to target -7%
🎯 on AMGN : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Aug 7, 27
matures : Aug 7, 27
■ Market Perform neutral · not a buy · 🎯$345
Price at call : $410.95 — gap to target -16%
Today : $436.99 — gap to target -21%
🎯 on AMGN : no call matured yet · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
See the other 77 calls, newest to oldest
▲ Buy · 🎯$440
Price at call : $404.85 — upside +9%
Today : $436.99 — upside +1%
🎯 on AMGN : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
▲ Buy · 🎯$452
Price at call : $404.85 — upside +12%
Today : $436.99 — upside +3%
🎯 on AMGN : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
Truist Securities ↗
Aug 5, 26
■ Hold neutral · not a buy · 🎯$362
Price at call : $404.85 — gap to target -11%
Today : $436.99 — gap to target -17%
🎯 on AMGN : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
Oppenheimer ↗
Aug 5, 26
▲ Outperform · 🎯$450
Price at call : $404.85 — upside +11%
Today : $436.99 — upside +3%
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
Scotiabank ↗
Aug 5, 26
▲ Sector Outperform · 🎯$450
Price at call : $404.85 — upside +11%
Today : $436.99 — upside +3%
🎯 on AMGN : no call matured yet · 📊 on Health : 33.3% · -8.8% (9 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
RBC Capital ↗
Aug 5, 26
▲ Outperform · 🎯$400
Price at call : $404.85 — upside -1%
Today : $436.99 — upside -8%
🎯 on AMGN : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
Wells Fargo ↗
Aug 5, 26
■ Equal-Weight neutral · not a buy · 🎯$400
Price at call : $404.85 — gap to target -1%
Today : $436.99 — gap to target -8%
🎯 on AMGN : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
BMO Capital ↗
Aug 5, 26
▲ Outperform · 🎯$450
Price at call : $407.83 — upside +10%
Today : $436.99 — upside +3%
🎯 on AMGN : no call matured yet · 📊 on Health : 60.7% · +8.8% (239 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
■ Equal-Weight neutral · not a buy · 🎯$360
Price at call : $387.64 — gap to target -7%
Today : $436.99 — gap to target -18%
🎯 on AMGN : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
▲ Buy · 🎯$420
Price at call : $355.25 — upside +18%
Today : $436.99 — upside -4%
🎯 on AMGN : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
Guggenheim ↗
Jul 13, 26
■ Neutral neutral · not a buy · 🎯$343
Price at call : $360.45 — gap to target -5%
Today : $436.99 — gap to target -22%
🎯 on AMGN : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
Morgan Stanley ↗
Jul 8, 26
■ Equal-Weight neutral · not a buy · 🎯$333
Price at call : $363.62 — gap to target -8%
Today : $436.99 — gap to target -24%
🎯 on AMGN : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
Truist Securities ↗
Jul 7, 26
■ Hold neutral · not a buy · 🎯$340
Price at call : $368.1 — gap to target -8%
Today : $436.99 — gap to target -22%
🎯 on AMGN : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
Cantor Fitzgerald ↗
Jul 6, 26
■ Neutral neutral · not a buy · 🎯$350
Price at call : $366.44 — gap to target -4%
Today : $436.99 — gap to target -20%
🎯 on AMGN : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Jul 6, 27
matures : Jul 6, 27
■ Neutral neutral · not a buy · 🎯$303
Price at call : $347.84 — gap to target -13%
Today : $436.99 — gap to target -31%
🎯 on AMGN : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Jun 16, 27
matures : Jun 16, 27
Morgan Stanley ↗
Jun 10, 26
■ Equal-Weight neutral · not a buy · 🎯$340
Price at call : $354.06 — gap to target -4%
Today : $436.99 — gap to target -22%
🎯 on AMGN : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jun 10, 27
matures : Jun 10, 27
Argus Research ↗
May 20, 26
▲ Buy · 🎯$375
Price at call : $331.57 — upside +13%
Today : $436.99 — upside -14%
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
in progress (365j)
matures : May 20, 27
matures : May 20, 27
Piper Sandler ↗
May 14, 26
▲ Overweight · 🎯$427
Price at call : $326.31 — upside +31%
Today : $436.99 — upside -2%
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : May 14, 27
matures : May 14, 27
Guggenheim ↗
May 4, 26
■ Neutral neutral · not a buy · 🎯$340
Price at call : $323.85 — gap to target +5%
Today : $436.99 — gap to target -22%
🎯 on AMGN : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : May 4, 27
matures : May 4, 27
Truist Securities ↗
May 1, 26
■ Hold neutral · not a buy · 🎯$327
Price at call : $323.85 — gap to target +1%
Today : $436.99 — gap to target -25%
🎯 on AMGN : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : May 1, 27
matures : May 1, 27
Canaccord Genuity ↗
Apr 21, 26
■ Hold neutral · not a buy · 🎯$366
Price at call : $345.92 — gap to target +6%
Today : $436.99 — gap to target -16%
🎯 on AMGN : no call matured yet · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Apr 21, 27
matures : Apr 21, 27
▲ Buy · 🎯$400
Price at call : $350.95 — upside +14%
Today : $436.99 — upside -8%
🎯 on AMGN : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Apr 13, 27
matures : Apr 13, 27
Morgan Stanley ↗
Apr 10, 26
■ Equal-Weight neutral · not a buy · 🎯$326
Price at call : $349.82 — gap to target -7%
Today : $436.99 — gap to target -25%
🎯 on AMGN : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Apr 10, 27
matures : Apr 10, 27
Guggenheim ↗
Apr 9, 26
■ Neutral neutral · not a buy · 🎯$351
Price at call : $351.02 — gap to target -0%
Today : $436.99 — gap to target -20%
🎯 on AMGN : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Apr 9, 27
matures : Apr 9, 27
Cantor Fitzgerald ↗
Apr 8, 26
■ Neutral neutral · not a buy · 🎯$350
Price at call : $349.81 — gap to target +0%
Today : $436.99 — gap to target -20%
🎯 on AMGN : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Apr 8, 27
matures : Apr 8, 27
■ Hold neutral · not a buy · 🎯$350
Price at call : $377.64 — gap to target -7%
Today : $436.99 — gap to target -20%
🎯 on AMGN : no call matured yet · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Mar 10, 27
matures : Mar 10, 27
■ Equal-Weight neutral · not a buy · 🎯$350
Price at call : $379.42 — gap to target -8%
Today : $436.99 — gap to target -20%
🎯 on AMGN : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 20, 27
matures : Feb 20, 27
Wells Fargo ↗
Feb 19, 26
■ Equal-Weight neutral · not a buy · 🎯$375
Price at call : $375.5 — gap to target -0%
Today : $436.99 — gap to target -14%
🎯 on AMGN : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
Piper Sandler ↗
Feb 18, 26
▲ Overweight · 🎯$432
Price at call : $379.73 — upside +14%
Today : $436.99 — upside -1%
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Feb 18, 27
matures : Feb 18, 27
Freedom Broker
Feb 12, 26
■ Hold neutral · not a buy · 🎯$375
Price at call : $366.2 — gap to target +2%
Today : $436.99 — gap to target -14%
🎯 on AMGN : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Feb 12, 27
matures : Feb 12, 27
Argus Research ↗
Feb 6, 26
▲ Buy · 🎯$400
Price at call : $375.82 — upside +6%
Today : $436.99 — upside -8%
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
in progress (365j)
matures : Feb 6, 27
matures : Feb 6, 27
Guggenheim ↗
Feb 6, 26
■ Neutral neutral · not a buy · 🎯$347
Price at call : $375.82 — gap to target -8%
Today : $436.99 — gap to target -21%
🎯 on AMGN : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Feb 6, 27
matures : Feb 6, 27
■ Neutral neutral · not a buy · 🎯$345
Price at call : $367.8 — gap to target -6%
Today : $436.99 — gap to target -21%
🎯 on AMGN : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
Morgan Stanley ↗
Feb 4, 26
■ Equal-Weight neutral · not a buy · 🎯$309
Price at call : $367.8 — gap to target -16%
Today : $436.99 — gap to target -29%
🎯 on AMGN : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
Cantor Fitzgerald ↗
Feb 4, 26
■ Neutral neutral · not a buy · 🎯$350
Price at call : $367.8 — gap to target -5%
Today : $436.99 — gap to target -20%
🎯 on AMGN : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
Leerink Partners ↗
Feb 4, 26
▲ Outperform · 🎯$355
Price at call : $366.2 — upside -3%
Today : $436.99 — upside -19%
🎯 on AMGN : no call matured yet · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
▲ Buy · 🎯$390
Price at call : $351.32 — upside +11%
Today : $436.99 — upside -11%
🎯 on AMGN : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jan 26, 27
matures : Jan 26, 27
■ Market Perform neutral · not a buy · 🎯$335
Price at call : $343.6 — gap to target -3%
Today : $436.99 — gap to target -23%
🎯 on AMGN : no call matured yet · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : Jan 20, 27
matures : Jan 20, 27
Truist Securities ↗
Jan 8, 26
■ Hold neutral · not a buy · 🎯$319
Price at call : $326.1 — gap to target -2%
Today : $436.99 — gap to target -27%
🎯 on AMGN : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jan 8, 27
matures : Jan 8, 27
Morgan Stanley ↗
Dec 12, 25
■ Equal-Weight neutral · not a buy · 🎯$304
Price at call : $325.31 — gap to target -7%
Today : $436.99 — gap to target -30%
🎯 on AMGN : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 12, 26
matures : Dec 12, 26
Wells Fargo ↗
Dec 10, 25
■ Equal-Weight neutral · not a buy · 🎯$325
Price at call : $317.38 — gap to target +2%
Today : $436.99 — gap to target -26%
🎯 on AMGN : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Dec 10, 26
matures : Dec 10, 26
BMO Capital ↗
Dec 3, 25
▲ Outperform · 🎯$372
Price at call : $345.42 — upside +8%
Today : $436.99 — upside -15%
🎯 on AMGN : no call matured yet · 📊 on Health : 60.7% · +8.8% (239 calls)
in progress (365j)
matures : Dec 3, 26
matures : Dec 3, 26
Leerink Partners ↗
Nov 27, 25
▲ Outperform · 🎯$305
Price at call : $345.46 — upside -12%
Today : $436.99 — upside -30%
🎯 on AMGN : no call matured yet · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Nov 27, 26
matures : Nov 27, 26
Piper Sandler ↗
Aug 25, 25
▲ Overweight · 🎯$342
Price at call : $289.58 — upside +18%
Today : $436.99 — upside -22%
Expected +18% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+52.1%
stock +52% · XLV +27%
matured Aug 25, 26
Piper Sandler ↗
Jun 27, 25
▲ Overweight · 🎯$328
Price at call : $279.21 — upside +17%
Today : $436.99 — upside -25%
Expected +17% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+29.1%
stock +29% · XLV +19%
matured Jun 27, 26
Piper Sandler ↗
May 16, 25
▲ Overweight · 🎯$328
Price at call : $275.85 — upside +19%
Today : $436.99 — upside -25%
Expected +19% · Actual +18% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+17.6%
stock +18% · XLV +8%
matured May 16, 26
Piper Sandler ↗
Feb 10, 25
▲ Overweight · 🎯$329
Price at call : $294.79 — upside +12%
Today : $436.99 — upside -25%
Expected +12% · Actual +24% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+23.7%
stock +24% · XLV +6%
matured Feb 10, 26
Piper Sandler ↗
Jan 2, 25
▲ Overweight · 🎯$310
Price at call : $259.28 — upside +20%
Today : $436.99 — upside -29%
Expected +20% · Actual +26% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+26.4%
stock +26% · XLV +13%
matured Jan 2, 26
Oppenheimer ↗
Aug 7, 24
▲ Outperform · 🎯$380
Price at call : $324.69 — upside +17%
Today : $436.99 — upside -13%
Expected +17% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-11.2%
stock -11% · XLV -13%
matured Aug 7, 25
Argus Research ↗
Jun 27, 24
▲ Buy · 🎯$340
Price at call : $312.45 — upside +9%
Today : $436.99 — upside -22%
Expected +9% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
-10.6%
stock -11% · XLV -8%
matured Jun 27, 25
Oppenheimer ↗
Feb 1, 24
▲ Outperform · 🎯$350
Price at call : $323.19 — upside +8%
Today : $436.99 — upside -20%
Expected +8% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-10.6%
stock -11% · XLV +4%
matured Jan 31, 25
Daiwa Capital ↗
Dec 21, 23
▲ Buy · 🎯$320
Price at call : $279.33 — upside +15%
Today : $436.99 — upside -27%
Expected +15% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 0% (1 call matured) · 📊 on Health : 40% · -1.0% (5 calls)
-5.7%
stock -6% · XLV +3%
matured Dec 20, 24
Oppenheimer ↗
Oct 25, 23
▲ Outperform · 🎯$310
Price at call : $272.16 — upside +14%
Today : $436.99 — upside -29%
Expected +14% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
+16.0%
stock +16% · XLV +18%
matured Oct 24, 24
Oppenheimer ↗
Oct 20, 23
▲ Outperform · 🎯$300
Price at call : $273.06 — upside +10%
Today : $436.99 — upside -31%
Expected +10% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
+16.0%
stock +16% · XLV +19%
matured Oct 19, 24
Argus Research ↗
Oct 17, 23
▲ Buy · 🎯$310
Price at call : $283.58 — upside +9%
Today : $436.99 — upside -29%
Expected +9% · Actual +13% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+13.3%
stock +13% · XLV +17%
matured Oct 16, 24
Oppenheimer ↗
Oct 9, 23
▲ Outperform · 🎯$290
Price at call : $271.25 — upside +7%
Today : $436.99 — upside -34%
Expected +7% · Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
+18.9%
stock +19% · XLV +17%
matured Oct 8, 24
Argus Research ↗
Sep 18, 23
▲ Buy · 🎯$280
Price at call : $264.31 — upside +6%
Today : $436.99 — upside -36%
Expected +6% · Actual +26% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+26.0%
stock +26% · XLV +18%
matured Sep 17, 24
Oppenheimer ↗
Jul 25, 23
▲ Outperform · 🎯$280
Price at call : $235.31 — upside +19%
Today : $436.99 — upside -36%
Expected +19% · Actual +43% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
+42.6%
stock +43% · XLV +10%
matured Jul 24, 24
Argus Research ↗
Jun 26, 23
▲ Buy · 🎯$260
Price at call : $222.61 — upside +17%
Today : $436.99 — upside -41%
Expected +17% · Actual +41% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+40.5%
stock +41% · XLV +12%
matured Jun 25, 24
Oppenheimer ↗
May 18, 23
▲ Outperform · 🎯$280
Price at call : $224.23 — upside +25%
Today : $436.99 — upside -36%
Expected +25% · Actual +39% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
+39.4%
stock +39% · XLV +12%
matured May 17, 24
Piper Sandler ↗
Apr 28, 23
▲ Overweight · 🎯$288
Price at call : $238.9 — upside +21%
Today : $436.99 — upside -34%
Expected +21% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+15.7%
stock +16% · XLV +5%
matured Apr 27, 24
Oppenheimer ↗
Apr 24, 23
▲ Outperform · 🎯$290
Price at call : $244.45 — upside +19%
Today : $436.99 — upside -34%
Expected +19% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
+11.9%
stock +12% · XLV +5%
matured Apr 23, 24
Oppenheimer ↗
Feb 1, 23
▲ Outperform · 🎯$294
Price at call : $246.41 — upside +19%
Today : $436.99 — upside -33%
Expected +19% · Actual +32% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
+31.7%
stock +32% · XLV +6%
matured Feb 1, 24
Piper Sandler ↗
Jan 19, 23
▲ Overweight · 🎯$293
Price at call : $262.03 — upside +12%
Today : $436.99 — upside -33%
Expected +12% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+17.5%
stock +17% · XLV +5%
matured Jan 19, 24
Piper Sandler ↗
Dec 13, 22
▲ Overweight · 🎯$299
Price at call : $272.26 — upside +10%
Today : $436.99 — upside -32%
Expected +10% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+3.4%
stock +3% · XLV -3%
matured Dec 13, 23
Oppenheimer ↗
Dec 6, 22
▲ Outperform · 🎯$310
Price at call : $283.29 — upside +9%
Today : $436.99 — upside -29%
Expected +9% · Actual -5% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-4.9%
stock -5% · XLV -4%
matured Dec 6, 23
Piper Sandler ↗
Nov 4, 22
▲ Overweight · 🎯$278
Price at call : $269.04 — upside +3%
Today : $436.99 — upside -36%
Expected +3% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+1.4%
stock +1% · XLV -2%
matured Nov 4, 23
Piper Sandler ↗
Aug 5, 22
▲ Overweight · 🎯$265
Price at call : $246.25 — upside +8%
Today : $436.99 — upside -39%
Expected +8% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+2.7%
stock +3% · XLV +2%
matured Aug 5, 23
Oppenheimer ↗
Jun 1, 22
▲ Outperform · 🎯$290
Price at call : $248.28 — upside +17%
Today : $436.99 — upside -34%
Expected +17% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-12.2%
stock -12% · XLV -1%
matured Jun 1, 23
Piper Sandler ↗
Apr 28, 22
▲ Overweight · 🎯$260
Price at call : $238.13 — upside +9%
Today : $436.99 — upside -41%
Expected +9% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
+0.7%
stock +1% · XLV -0%
matured Apr 28, 23
Oppenheimer ↗
Feb 9, 22
▲ Outperform · 🎯$285
Price at call : $237.19 — upside +20%
Today : $436.99 — upside -35%
Expected +20% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 67% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
+1.2%
stock +1% · XLV -2%
matured Feb 9, 23
Piper Sandler ↗
Feb 3, 21
▲ Overweight · 🎯$260
Price at call : $237.08 — upside +10%
Today : $436.99 — upside -41%
Expected +10% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 92% (12 calls matureds) · 📊 on Health : 46.7% · -1.3% (321 calls)
-5.5%
stock -6% · XLV +15%
matured Feb 3, 22
Argus Research ↗
Dec 9, 19
▲ Buy · 🎯$265
Price at call : $232.82 — upside +14%
Today : $436.99 — upside -39%
Expected +14% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
-1.7%
stock -2% · XLV +13%
matured Dec 8, 20
Argus Research ↗
Jan 23, 18
▲ Buy · 🎯$220
Price at call : $191.99 — upside +15%
Today : $436.99 — upside -50%
Expected +15% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+5.0%
stock +5% · XLV +1%
matured Jan 23, 19
Argus Research ↗
Jul 27, 17
▲ Buy · 🎯$195
Price at call : $174.54 — upside +12%
Today : $436.99 — upside -55%
Expected +12% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+9.2%
stock +9% · XLV +10%
matured Jul 27, 18
Argus Research ↗
Feb 8, 16
▲ Buy
Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+16.7%
stock +17% · XLV +13%
matured Feb 7, 17
Argus Research ↗
Jan 25, 13
▲ Buy
Actual +42% · Reason (≥ +15%) : ✓ Yes
🎯 on AMGN : 78% (9 calls matureds) · 📊 on Health : 55.7% · +2.6% (158 calls)
+42.1%
stock +42% · XLV +29%
matured Jan 25, 14
Frequently asked questions
Should I buy Amgen stock?
This isn't buy advice. For Amgen, the analyst consensus is "Hold", with an average price target of $400 (-8% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (5 calls tracked on Amgen). We show the numbers — you decide.
Is it too late to buy Amgen? How high can it go?
The most bullish analyst target on Amgen is $460 (+5% above today's price); the average is $400. That's the upside they see. Check how reliable those analysts have actually been on Amgen on our site before trusting it.
Is Amgen still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 24 analysts have a real record on Amgen, the best hitting 100% over 5 calls. Current consensus: "Hold". Make your call on data, not noise.
Should you invest in Amgen? The case for and against
The arguments for and against, one by one, from the numbers: why invest in AMGN (and why hesitate).
What has Amgen's past performance been?
Historical returns and a "how much if I had invested" calculator: AMGN performance & returns.
Does Amgen pay a dividend?
Yield, consistency and growth history of the dividend: AMGN's dividend.
What is the best month to buy AMGN?
The 12 months ranked by the stock's past returns: best & worst month to buy AMGN.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX